Supernus Pharmaceuticals (LTS:0LB2) Total Liabilities : $374.9 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Supernus Pharmaceuticals Total Liabilities?

Supernus Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 was $374.9 Mil.

Supernus Pharmaceuticals's quarterly Total Liabilities declined from Sep. 2023 ($372.97 Mil) to Dec. 2023 ($356.16 Mil) but then increased from Dec. 2023 ($356.16 Mil) to Mar. 2024 ($374.92 Mil).

Supernus Pharmaceuticals's annual Total Liabilities declined from Dec. 2021 ($873.30 Mil) to Dec. 2022 ($816.30 Mil) and declined from Dec. 2022 ($816.30 Mil) to Dec. 2023 ($356.16 Mil).

Supernus Pharmaceuticals Total Liabilities Historical Data

The historical data trend for Supernus Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals Total Liabilities Chart

Supernus Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

564.85

759.24

873.30

816.30

356.16

Supernus Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															879.66	373.19	372.97	356.16	374.92

Supernus Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Supernus Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	290.196	+	(33.196	+	7.802
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	24.963	+	0)
	=	356.2

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1277.673	-	921.516
	=	356.2

Supernus Pharmaceuticals's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	314.554	+	(32.994	+	7.875
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	19.501	+	0)
	=	374.9

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	1304.09	-	929.166
	=	374.9

Supernus Pharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Supernus Pharmaceuticals (LTS:0LB2) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (LTS:0LB2) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

SUPN:USA S49:Germany

Address

9715 Key West Avenue, Rockville, MD, USA, 20850

Website

https://www.supernus.com

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Supernus Pharmaceuticals (LTS:0LB2) Headlines

No Headlines